
    
      This company-sponsored study is an one-arm, prospective, and, cohort-observational study in
      pediatrics (less than 15 years old) administered Ciproxan injection. All patients in the
      contracted institute should be enrolled into this study. Consequently 45 cases will be is
      planned to be enrolled in three-year period Target population is pediatrics with a diagnosis
      of complicated cystitis, pyelonephritis, cystic fibrosis, or anthrax infected by
      ciprofloxacin-active microorganisms, i.e. Bacillus anthracis, Escherichia coli, Pseudomonas
      aeruginosa. The treatment should be performed based on the product label in Japan. The
      standard observation will be performed until the last date of the treatment.
    
  